Literature DB >> 19727093

What is the rate of loss of response to infliximab therapy in Crohn's disease?

Jingdong Chao, Parvez Mulani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19727093     DOI： 10.1038/ajg.2009.375

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  2 in total

Review 1.  Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn's disease.

Authors:  Yun Qiu; Bai-Li Chen; Ren Mao; Sheng-Hong Zhang; Yao He; Zhi-Rong Zeng; Shomron Ben-Horin; Min-Hu Chen
Journal:  J Gastroenterol       Date:  2017-03-08       Impact factor: 7.527

2.  Infliximab dosing patterns in a sample of patients with Crohn's disease: results from a medical chart review.

Authors:  Joseph Tkacz; Jennifer H Lofland; Julie Vanderpoel; Charles Ruetsch
Journal:  Am Health Drug Benefits       Date:  2014-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.